Literature DB >> 12605396

HIV-related Hodgkin's disease with central nervous system involvement and association with Epstein-Barr virus.

Suleiman Massarweh1, Mark M Udden, Imran Shahab, Michael Kroll, David A Sears, Garrett R Lynch, Bin S Teh, Hsin H Lu.   

Abstract

Central nervous system (CNS) involvement is a rare occurrence in the course of human immunodeficiency virus (HIV)-related Hodgkin's disease (HD). We report the clinical course of a patient with HIV infection who developed systemic HD, mixed cellularity subtype, later complicated by leptomeningeal involvement. The patient died from his illness, and autopsy was performed. Examining the brain lesion, Epstein-Barr virus (EBV) presence was demonstrated in Reed-Sternberg cells by immunohistochemistry using an EBER probe for EBV RNA. This is the second case report in the English literature of HD involving the CNS in an HIV-positive individual, and the first demonstrating EBV presence. Extranodal presence of Hodgkin's disease in patients with HIV infection is probably related to immunosuppression, and physicians treating this illness should be alert to the potential of unusual sites of involvement. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12605396     DOI: 10.1002/ajh.10288

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  3 in total

1.  Central nervous system Hodgkin lymphoma: case report and review of the literature.

Authors:  Sara Torgerson; Horatiu Olteanu; Matthew Tinguely; Timothy S Fenske
Journal:  J Neurooncol       Date:  2010-07-31       Impact factor: 4.130

2.  Intracranial Hodgkin's lymphoma in an HIV positive patient.

Authors:  Kevin Ramchandar; L H Verhey; Neilank K Jha; N K Murty; William McMillan
Journal:  J Neurooncol       Date:  2008-04-09       Impact factor: 4.130

Review 3.  Rare central nervous system lymphomas.

Authors:  Furqaan Ahmed Kaji; Nicolás Martinez-Calle; Vishakha Sovani; Christopher Paul Fox
Journal:  Br J Haematol       Date:  2022-03-16       Impact factor: 8.615

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.